Answers are grounded in this paper and cite their sources.
Case report demonstrates effective anti-HER2 therapy in HER2-positive rectal adenocarcinoma with liver metastasis, suggesting its potential benefit.
Human epidermal growth factor receptor 2 (HER2) positivity, including gene amplification and mutation, is uncommon in colorectal cancer (CRC), with an incidence of only ~5%. Targeted HER2 therapy has been shown to be feasible in patients with HER2-positive CRC after the failure of standard treatments. However, the importance of anti-HER2 therapy in patients with HER2-positive CRC is not yet fully reflected in clinical guidelines. The present report describes the case of a 60-year-old female patient who presented with abdominal pain and bloody stools and was diagnosed with rectal adenocarcinoma and liver metastasis. The next-generation sequencing of biopsy tissue obtained during colonoscopy suggested HER2 mutation/amplification. After two cycles of chemotherapy, the tumor marker levels of the patient continued to increase, indicating poor treatment efficacy. The patient subsequently received six cycles of chemotherapy combined with anti-HER2 therapy, leading to a reduction in tumor marker levels and gradual shrinkage of the lesions. After this, the colorectal and liver lesions were surgically removed. There is currently no definitive treatment for HER2-positive CRC. However, the present case highlights a favorable response to anti-HER2 therapy in a patient with HER2-positive metastatic CRC, suggesting that this treatment approach may be beneficial for HER2-positive CRC and warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: